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Background: Ewing’s sarcoma is a malignancy characterized by a specific 11:22 chromosomal translocation which
generates a novel EWS-FLI1 fusion protein functioning as an aberrant transcription factor. In the present study, we
have further characterized the junction region of the EWS-FLI1 fusion protein.
Methods: In-silico model of EWS-FLI1 fusion protein was analysed for ligand binding sites, and a putative region
(amino acid (aa) 251–343 of the type 1 fusion protein) in the vicinity of the fusion junction was cloned and
expressed using bacterial expression. The recombinant protein was characterized by Circular Dichroism (CD). We
then expressed aa 251–280 ectopically in Ewing’s sarcoma cell-line and its effect on cell proliferation, tumorigenicity
and expression of EWS-FLI1 target genes were analysed.
Results: Our modelling analysis indicated that Junction region (aa 251–343) encompasses potential ligand biding
sites in the EWS-FLI1 protein and when expressed in bacteria was present as soluble form. Ectopically expressing
this region in Ewing’s sarcoma cells inhibited tumorigenicity, and EWS-FLI1 target genes indicating a dominant
negative biological effect.
Conclusions: Junction region can be exploited further as target for drug development in future to specifically
target EWS-FLI1 in Ewing’s Sarcoma.Background
Ewing’s sarcoma is a highly malignant bone and soft tis-
sue tumor occurring in children and young adults. More
than 85% of the Ewing’s sarcoma family of tumours
(ESFT) patients present with a balanced t(11:22) (q24;
q12) chromosomal translocation [1,2]. This reciprocal
translocation generates a novel in frame fusion gene
with a unique junctional region between sequences
which encode the N-terminus of the RNA binding pro-
tein EWS from chromosome 22 and the C-terminus of
FLI1 transcription factor on chromosome 11 [3,4]. Sev-
eral evidences have shown EWS-FLI1 as a well described
oncogene and with depletion of this gene product result-
ing in inhibition of ESFT growth. EWS-FLI1 fusion pro-
tein therefore is a validated tumor target functioning as
an aberrant transcription factor [4,5]. Transforming* Correspondence: drtrajkumar@gmail.com
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reproduction in any medium, provided the oractivity of EWS-FLI1 requires both the EWS portion of
the fusion protein which contributes to transactivation
and the ETS domain (FLI1 portion) which mediates
sequence-specific DNA binding [6-8].
Structure of EWS-FLI1 is not available in the PDB and
it is an intrinsically disordered Protein (IDP). These kind
of proteins are insoluble, unstructured and do not have
specific Ramachandran angles in the protein backbone
and show polymorphism in bound state [9,10].
In this study, we looked at EWS-FLI1 protein struc-
ture using modelling tool and bioinformatics tools to
analyze potential structure in-silico. Our analysis indi-
cated potential ligand binding sites which encompass the
junction region of the EWS-FLI1 protein and that the
region was likely to have a structure indicated by alpha
helical and beta pleated structures. The junction region
(aa 251–343) containing type 1 fusion residues was
expressed and purified and subjected to circular dichro-
ism (CD) analysis. Finally our analysis of the biological
effects of ectopically expressing junction region on. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Jully et al. BMC Cancer 2012, 12:513 Page 2 of 10
http://www.biomedcentral.com/1471-2407/12/513expression of EWS-FLI1 target genes, and proliferation
of Ewing’s sarcoma cells in-vitro indicates a dominant
negative function for the junction region.
Methods
RNA Extraction and cDNA preparation
The study was approved by the Cancer Institute Ethics
Committee. RNA was isolated from biopsy sample from
a patient diagnosed with Ewing’s Sarcoma after an
informed consent. RNA was qualitatively and quantita-
tively assessed on 1.25% agarose gel and by spectropho-
tometer. cDNA was synthesized using Superscript II
(Invitrogen) as per manufacturer’s instructions and β
actin amplification was done to check its quality. Full
length EWS-FLI1 Type1 fusion gene was amplified. The
PCR product was purified and sequenced using ABI 310
Genetic analyzer. This sequence was submitted in
GenBank [GenBank: ACA62796].
In-silico analysis of EWS-FLI1 protein using prime and
SiteMap
Prime (Version 3.0, Schrodinger, LLC, New York) was
used to build EWS-FLI1 structure. The OPLS2000 all-
atom force field was used for energy scoring of proteins.
Surface Generalized Born (SGB) continuum solvation
model, was used for treating solvation effects; and side
chain rotomer and backbone dihedral libraries derived
from PDB non-redundant structures were used for
building backbone and side chains. The modelled struc-
ture was imported and corrections were carried out by
Protein Preparation wizard of Schrodinger, where hydro-
gens were added automatically and refinement of the
structure was done. EWS-FLI1 protein was assessed for
putative ligand binding sites using SiteMap. The
programme highlights regions within the protein suit-
able for occupancy by hydrophobic groups or by ligand
hydrogen-bond donors, acceptors, or metal-binding
functionality. SiteScore, the scoring function was used to
assess a site's propensity for ligand binding, and rank
possible binding sites.
Cloning and expression of EWS-FLI1
The sequenced EWS-FLI1 Type 1 fusion gene was
cloned in pET 102/D-TOPO vector (Invitrogen) using
the primer set PET 102/D-TOPO Forward. 5’CAC
CATGGCGTCCACGGATT3’ and Reverse. 5’GTAG
TAGCTGCCTAAGTGTGA 3’. Full length EWS-FLI1
type 1 c-DNA was cloned into pCR2.1 using TA cloning
method. The insert was then subcloned into pGEX-KG a
GST fusion vector to be expressed as GST fusion pro-
tein. Ligation mixtures of EWS-FLI1 in pET 102/D
TOPO and pGEX-KG were used to transform E.coli
TOP 10, chemically competent cells and selected in ampi-
cillin (100 μg/ml) containing medium. The positive cloneswere determined by colony PCR and sequencing. Full
length EWS-FLI1 was cloned into pGEX-KG and pET
102/D-TOPO vector were expressed in BL21-CodonPlus
(DE3)-RP competent cells (Stratagene, La Jolla, CA) con-
taining extra copies of ArgU and ProL genes to overcome
the codon bias [11]. Protein production was initiated by
adding 0.4 mM isopropyl β-D-1- thio galactopyranoside
(IPTG), and bacteria were cultured for an additional 3–4 h
at 20°C.
Immunoblotting
Lysates from Bacteria cells expressing Thioredoxin
(Trx)-EWS-FLI1-His tagged protein, whole cell lysates
from MCF-7, EWS502 cells stably expressing pCDNA/
FLAG and pCDNA/FLAG/Junction (aa 251–280) con-
structs were used for immunoblot analysis. The anti-
bodies used were anti-FLI1 (C-19) antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) , E Cadherin
(abcam, Cambridge, UK), Vimentin (abcam, Cambridge,
UK), Beta Actin (Sigma, Saint Louis, MI, USA). Bacteria
cells expressing Thioredoxin (Trx)-EWS-FLI1-His tagged
protein, suspended in native lysis buffer (20 mM Tris pH
8, 500 mM NaCl, 0.1%NP 40, Lysozyme 1mg/ml),
subjected to lysis by sonication and centrifuged at 12000
rpm. The supernatant (soluble) and pellet (insoluble)
fraction were analysed in SDS PAGE (10%). Lysates from
MCF-7, and EWS502 cells stably expressing pCDNA/
FLAG or pCDNA/FLAG/Junction (aa 251–280) con-
structs were prepared in RIPA buffer (1% Nonidet P-40,
1% sodium deoxycholate, 0.1% SDS, 0.15M Sodium
chloride, 0.05M Tris.Cl, pH8.0). 50 micro grams of the
whole cell lysate was used for the analysis. Gels were
transferred onto poly vinylidene difluoride (PVDF)
membrane (Millipore, Billerica, MA, USA). This filter was
blocked with 5% non-fat milk in TBS-T (20 mM Tris–HCl,
pH 7.5, 150 mM NaCl, 0.1% Tween 20) for 1 hr at room
temperature and then probed with respective primary and
secondary antibody. The blot was incubated and visualized
with enhanced chemiluminescence (ECL) solution (GE
Healthcare Life Sciences, Buckinghamshire, UK) according
to the manufacturer’s instructions.
Purification of recombinant EWS-FLI1
Trx-Full length EWS-FLI1-6xHis tagged Protein was
purified by Ni-NTA immobilized metal-ion affinity chro-
matography (IMAC) under denaturing conditions. Lysis/
Equilibration buffer/wash buffer compositions: 50 mM
Na3PO4 (pH 7.8) containing 500 mM NaCl, 20 mM Tris
HCl, 6 M Urea and Elution buffer: wash buffer contain-
ing 200mM imidazole. Initially, precharged metal chelat-
ing columns were washed twice with 10 mL of distilled
water, and equilibrated in 10 mL of equilibration buffer.
Cell pellet corresponding to 100 mL of bacterial culture
was re-suspended in 10 mL of lysis buffer. Debris was
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The supernatant was applied to Ni-NTA affinity column
(Invitrogen, Carlsbad, CA, USA ) and incubated at room
temperature for 30 minutes with constant rocking [12].
Column was washed three times and protein was then
eluted from the column using 200mM imidazole. Ali-
quots (1 mL) were collected and a portion of which was
then applied to 10% polyacrylamide gel for Coomassie
staining and immunoblotting.Tryptic mapping and mass spectrometry
Mass spectrometry of the purified EWS-FLI1 was per-
formed at the Mass Spectroscopy Facility at The Centre
for Genomics Research, New Delhi, India.Fold index plot
Amino acid sequence of EWS-FLI1 (submitted in Gen-
Bank) was assessed to identify the ordered and disor-
dered region within the protein using Fold Index
predictor available as a graphic web server [13,14].Purification of soluble junction construct
Junction (aa 251 – 343) region was cloned in pET 102/
D-TOPO vector (Invitrogen Carlsbad, CA, USA) using
primer set Junction (aa 251 – 343) Forward. 5’CACCC
CAAGTCAATATAGCAACAGAGC 3’, and Junction (aa
251 – 343) Reverse. 5’GGCGTTGGCGCTGTCGGAG 3’
and expressed in BL21-CodonPlus (DE3)-RP competent
cells. Expression of Trx-Junction (aa 251–343) -6xHis
tagged protein was confirmed by immunoblotting
using anti-thio antibody and horseradish peroxidase-
conjugated anti-mouse antibodies as primary and sec-
ondary antibody, respectively. Protein was purified by
Ni-NTA immobilized metal-ion affinity chromatog-
raphy (IMAC) under native condition. Buffer compo-
sitions were: Lysis/Binding/Equilibration buffer 50
mM sodium phosphate buffer, 300 mM NaCl, 5 mM
imidazole, 0.1%NP-40 pH 8.0. Wash (W1) 50 mM so-
dium phosphate buffer, 300 mM NaCl, 20 mM imid-
azole, pH 8.0. Wash (W2) 50 mM sodium phosphate
buffer, 300 mM NaCl, 50 mM imidazole, pH 8.0. Elu-
tion buffer 50 mM sodium phosphate buffer, 300 mM
NaCl, 200 mM imidazole, pH 8.0.Dialysis and circular dichroism
Affinity purified Junction protein (aa 251–343) in buffer
containing 50 mM sodium phosphate buffer, 300 mM
NaCl, 200 mM imidazole, pH 8.0 was concentrated
using Centricon concentrator (EMD Millipore, Billerica,
MA, USA) with a 10 kDa cut off and dialyzed against
10 mM sodium phosphate buffer, pH 8.0. The concentrated
protein (2mg/ml) was subjected to circular dichroism.Expression of short junction region (aa 251 to aa 280) in
Ewing Sarcoma cells
The short junction construct, a 30 amino acid contain-
ing peptide (aa 251 to aa 280) which overlaps EWS-FLI1
junction region was cloned into pcDNA3.1/FLAG vector
at EcoRV and XhoI restriction sites using the primer set
(aa 251 to aa 280) Forward. 5’GATATCCCAAGTCAAA
TAACCCAACAGAG 3’ and (aa 251 to aa 280) Reverse
5’CTCGAGCTACATGTTATTGCCCCA 3’. EWS502
Ewing’s sarcoma cell line was grown in RPMI-1640 sup-
plemented with 10 % fetal calf serum. 5 μg of pCDNA3.1/
FLAG-junction and pCDNA3.1/FLAG plasmid alone were
transfected separately into EWS502 cell line (harbouring
EWS-FLI1 type1 fusion gene) using Fugene (Roche, Mo-
lecular Biochemicals, Indianapolis, IN, USA) transfection
kit as per the manufacturer’s instructions. The transfected
cell line was selected in 100μg/ml hygromycin and main-
tained in presence of hygromycin. Single clone of trans-
fected cells was isolated by serial dilution. Expression of
Flag tagged junction construct in transfected EWS502 cell
line was confirmed by western blot.
Colony forming assay
EWS502 pCDNA/FLAG alone and EWS502 pCDNA/
FLAG/junction (aa 251–280) cells were plated in agar in
duplicates at density of 5000 cells per well in a 6 well
culture plate. Bottom layer was prepared with 0.5% agar
and top layer with 0.2% agar. Culture plates were incu-
bated at 37°C and 5% CO2 in a humidified atmosphere.
Colonies were enumerated after 3 weeks of growth. All
the experiments were repeated at least twice.
Real-Time quantitative PCR
Real time quantitation of EWS-FLI1 modulated targets
NROB1, NKX2.2, GLI1, Cyclin D1, c-MYC, EZH2,
TGFβIIR, KFL2 and EMT markers E-Cadherin, Vimentin,
Slug, N-Cadherin and Fibronectin was done using SYBR
green master mix (Fermentas GMBH, Germany) as per
manufacturer’s instructions. Three individual clones of the
junction construct (aa 251–280) transfected EWS502 were
analyzed for Real time quantitation. Each sample was
assessed in triplicate to ensure reproducibility of the quan-
titative measurements. GAPDH expression was evaluated
for each sample as a control for total RNA. The experi-
ments were repeated at least twice.
Results
Junction region (aa 251 to aa 343) encompasses potential
ligand binding sites in the EWS-FLI1 protein
Since the crystal structure of EWS-FLI1 protein was not
available we chose to study the putative structure of the
protein modelled using an proprietary algorithm insilico.
The protein sequence of EWS-FLI1 accession number
ACA62796 was used for modelling. The modelled
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helices (30–37, 88–94, 116–120, 124–127, 254–262, 264–
268, 326–334, 401–412, 458–465), beta sheets (12–15,
54–57, 105–109, 147,148, 352,353, 377–380, 387–
389,425,426) and loops (Figure 1A). We examined the
protein structure for potential ligand association sites.
Sites which received a score greater than 1.0 indicate that
they are likely to bind with ligands. Around 5 sites were
identified, of which four sites had a site score greater than
1 and encompassed the junction region amino acids
(Table 1). Sites 1 and 6 are depicted in Figure 1B and C.
Since junction region amino acids were predicted to be
part of the potential ligand binding sites we were inter-
ested in further understanding the structure in the vicinity
of the junction region. Analysis of the structure of junc-
tion region extending between aa 251 and aa 343 compris-
ing of both EWS region and FLI1 potion indicated the
presence of alpha helical regions (Figure 1D).
Further when analyzed using Fold index tool, the region
in the FLI1 portion of the junction indicated a stable region
which however did not extend into the EWS portion
(Figure 2). Since our modeling studies indicated a func-
tional role as a putative ligand binding region and presence
of structured regions in the junction region (aa 251–343)
we proceeded to express and purify the junction region.
Full Length protein is insoluble where as the junction
region (aa 251 to aa 343) is soluble
To start with we expressed the full length recombinant
EWS-FLI1 protein with a thioredoxin (Trx) tag in theFigure 1 In-silico structure of EWS-FLI1 protein and putative small mo
Figure 1B and C model structures denoting the small molecule binding reg
vicinity of the junction region of EWS-FLI1 protein.amino terminus and 6xHis-Tag in the carboxy terminus
was expressed in BL21-CodonPlus (DE3)-RP cells. A band
consistent with EWS-FLI1 (68 kDa) was observed in the
insoluble fraction (Figure 3A) which was confirmed by
western blot using Anti FLI1 antibody (Figure 3B). The in-
soluble fraction of EWS-FLI1 was purified using Ni-NTA
purification system in the denaturing condition
(Figure 3C). Similarly, GST-EWS-FLI1 could not be
taken further for native affinity purification because of
its insolubility. The junction region aa 251–343 identi-
fied from our modeling studies to be relatively struc-
tured was cloned and expressed in a similar manner to
the full length protein. The junction region was
expressed in soluble fraction of the lysate. Expression of
soluble junction region (aa 251–343) was confirmed by
Western blot (Figure 4A). Junction region was purified
in native condition using Ni-NTA purification system
(Figure 4B), concentrated and circular dichroism analysis
was performed. The CD readings were taken for the
wavelength range of 190-350nm showed highly coiled
form (random)- 48%, Beta sheets- 42% and alpha helix
10% (Figure 4C) indicating the presence of structured
regions in the protein.
Ectopic expression of junction construct (aa 251 to aa
280) represses tumorigenicity and alters the expression of
EWS-FLI1 target genes
In order to explore the biological effects of junction region
a smaller portion comprising of thirty amino acids (251 to
280) was ectopically expressed in EWS502 Ewing’slecule binding regions. A, In-silico structure of EWS-FLI1 protein.
ions. Figure 1D the structure of the region form a.a.251- a.a.343 in the
Table 1 Putative small molecule binding sites in EWS-FLI1 protein
SITE Residue Number Score
4 21,156–167,170,173,176-196,203-207,218- 223 247,248, 317–327, 389, 391, 394,447-450,454,498 1.151
3 109-112,117,120,121,124,125,128,129,146-148,150-153,298 305, 307, 308,310,315,317,324,325,327,328,331,332,335,345,347,380,382,383,385-
389, 481-490
1.077








The table lists the binding sites along with the amino acid residues which form the sites. Residues numbered in bold denote the region in the vicinity of the
junction of EWS-FLI1 protein.
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gion was confirmed by immunoblotting for the presence
of FLAG tagged junction region. (Figure 5A). The over ex-
pression was further confirmed by real-time PCR analysisFigure 2 Bioinformatics based Fold Index values for EWS-FLI1 type 1
between the ordered (upper case: green colored) and disordered (lower ca
extensive unfolded regions (below the 0 line threshold fold index) for the
and net charge of the sequence.which indicated an Log(2) fold increase of 5.96 in over
expressing cells (Figure 5B). When soft agar assay was per-
formed on these cells we found a marked reduction in the
colony forming propensity of EWS502 cells in theschematic translocation. Fold index plot shows the differentiation
se: red colored) based on the amino acid composition. The plot shows
EWS-FLI1 fusion protein based on the average residue hydrophobicity
Figure 3 Bacterial expression and purification of recombinant
full length EWS-FLI1. A: Coomassie stained SDS PAGE gel picture
showing,expression of Full Length Trx -EWS-FLI1-His tag Protein in
insoluble fraction.Lane 1 represents protein ladder, Lane2
represents soluble fraction , Lane 3 represents insoluble fraction.
B: Confirmation of EWS-FLI1 protein expression by immunoblotting
with anti FLI1 antibody. Lane 1: soluble fraction, Lane 2:insoluble
fraction. C: Coomassie stained SDS PAGE gel picture of Ni-NTA
Purification of full length EWS-FLI1 protein in denaturing
condition.Lane1: Protein ladder Lane 2: Uninduced cell lysate,
Lane 3: Induced cell lysate , Lane 4: Flow Through, Lane 5: Wash
and Lane 6: Elute.
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this indicated that the over expression of junction con-
struct could inhibit anchorage independence and hence
tumorigenicity of Ewing sarcoma cells.
Junction construct transfected EWS502 cells under-
went marked morphologic changes in vitro, adopting a
round, rather than the elongated phenotype of empty
vector transfected counterpart (Figure 5D).
Marked decrease in the colony forming ability
observed led us to study the expression of the known
EWS-FLI1 regulated targets. Real time quantitative
RT-PCR analysis of EWS-FLI1 up-regulated target
genes were found to be down-regulated in junction
construct (a.a. 251–280) transfected cell line - GLI1 by
2.47 fold, NKX2.2 by 2.3 fold, NROB1 by 3.15 fold,
Cyclin D1 by 2.4 fold, c-MYC 1.69 by fold, and EZH2
by 1.48 fold compared to pcDNA-EWS502 vector con-
trol cell line (Figure 6A). Known EWS-FLI1 down-
regulated targets like TGFβRII, and KLF2 showed
up-regulation of 11.9 fold and 4.85 fold respectively in
junction construct transfected EWS502 cells, compared
to vector control.Epithelial to mesenchymal transition (EMT) marker genes
expression is repressed in the junction construct (aa 251
to aa 280) over-expressing cells
The suppression of tumorigenic potential by the junc-
tion construct (aa 251–280) transfected cells also led us
to study the effect on expression of EMT markers.
Mesenchymal markers were found to be down regulated
(Figure 6B) in junction construct transfected EWS502 cell
line. Fibronectin (6.26 fold), Vimentin (1.75 fold) and N
Cadherin (5.69 fold) were down regulated compared to
vector control. EMT promoting gene Slug was also found
to be down regulated by 2.1 fold (Figure 6B).
Epithelial marker E-Cadherin showed 4 fold up regula-
tion in junction construct transfected EWS502 (compared
to vector control). Immunoblotting was performed to
assess the protein expression levels of E-Cadherin and
Vimentin relative to pCDNA/FLAG expressing cells. Cell
lysate from MCF-7 cells were used as positive control for
the expression of E-Cadherin and Vimentin and Beta Actin
expression as a control for protein loading. The analysis
showed a distinct increased expression of E Cadherin and
repression of Vimentin expression in junction construct
(aa 251–280) expressing cells (Figure 6C and D). The ex-
pression levels assessed for EMT marker genes further in-
dicate the potential of the junction construct (aa 251–280)
to repress tumorigenic properties Ewing’s sarcoma cells.
Discussion
EWS-FLI1 is an ideal therapeutic target protein in
Ewing’s sarcoma due to its causative role in the process
of tumorigenesis [15,16]. Structural and functional
characterization of EWS-FLI1 is therefore important to
specifically target this protein which is very likely to
benefit patients with Ewing’s sarcoma. Deeper under-
standing of its sequence structure relationships promises
to enable design of novel therapeutic molecules.
EWS-FLI1 is an intrinsically disordered protein and
structural property of this protein is less characterized due
to its insolubility. In the present study, we modelled the
EWS-FLI1 of type 1 fusion type in-silico and identified po-
tential ligand binding sites. The insolubility of the full
length EWS-FLI1 could not be overcome despite the
widely used solubility tags like Trx and GST. Recovery of
the protein in denaturing conditions and refolding was
not attempted in this study because studies done previ-
ously show, purified EWS-FLI1 and refolded EWS-FLI1
exhibiting differences in orientation of aromatic side
chains on exposure to solvent [17]. We therefore identified
the ordered region within the EWS-FLI1 structure which
had the junction region specific to EWS-FLI1 type 1 and
characterized it by circular dichroism (CD).
The junction region of any oncogenic fusion protein is
unique for targeting and we, for the first time found the
junction region (aa 251–343) of EWS-FLI1 fusion protein
Figure 4 Bacterial expression and purification of Junction region (aa 251- aa 343). A: Coomassie stained SDS PAGE gel picture of Ni-NTA
Purification of Junction- EWS-FLI1 protein under native condition. Lane1: Protein ladder, Lane 2: Induced cell lysate soluble fraction, Lane 3: Flow
Through, Lane 4: Wash and Lane 5: Elute. Figure 4B: Confirmation of junction region (aa 251–343) protein expression by immunoblotting with anti
Thio antibody. Lane 1: insoluble fraction, Lane 2: soluble fraction. Figure 4C: CD of junction region (aa 251-aa 343) of EWS-FLI1 soluble construct.
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ditions is a prerequisite for drug development, though
previous reports [17] have shown the insolubility of the
EWS-FLI1, our findings show that the junction region can
be obtained in the soluble form and can be used for further
structural exploration, with a potential to be a drug target.
Further work needs to be carried out to understand the
transition from a disordered to an ordered state by per-
forming CD experiments with titrations against possible
interacting proteins or other molecules (for e.g. Promoter
Oligonucleotides) regulated by this fusion protein [18-20].
This could be useful in obtaining a crystal structure for
the junction region of this fusion protein which would en-
able identifying a unique target.
As per our knowledge we are the first to describe the
dominant negative behaviour of the junction construct (aa
251 – 280). Previous study [7] with EWS-FLI1 deletion
mutants showed that both EWS and FLI1 domains arenecessary for transformation and deletion of either the
EWS domain or the FLI1 DNA-binding domain totally
abrogates the transforming ability. In our study we found
that the junction region behaved in a dominant negative
manner by suppressing tumorigenicity of EWS502 Ewing’s
Sarcoma cell line in the soft agar assay. This attenuation
could be an indirect effect due to competition for the mo-
lecular targets between the wild type EWSFLI1 present in
EWS502 and junction region protein which was ectopi-
cally overexpressed, or junction region protein interacting
with the full length wild type EWS-FLI1 rendering in-
active complexes between the two forms of protein.
Because previous studies [21], have suggested that
transcriptional activation is critical to the function of
EWS-FLI1 as an oncoprotein, we focused our efforts on
genes that were up regulated by the fusion protein.
Quantitative Real Time PCR was done to check the ex-
pression level of some of the well known EWS-FLI1 up
Figure 5 Over-expression of EWS-FLI1 junction region (aa 251- aa 280) inhibits tumorigenicity, EWS-FLI1 target gene expression and
EMT marker genes in Ewing’s sarcoma cells. A: Confirmation of junction region (aa 251–280) protein expression in transfected EWS502 cell
line by immunoblotting with anti Flag antibody. Lane 1: pCDNA/FLAG expressing EWS502 cells, Lane 2: pCDNA/FLAG/Junction (aa 251–280)
expressing EWS502 cells. Figure 5B: Real time RT-PCR analysis of Junction region (aa 251–280) in pCDNA/FLAG and pCDNA/FLAG/Junction
(aa 251–280) stably expressing EWS502 cells. The real time RT-PCR analysis was performed using the same primer set used to clone the junction
region and SYBR green chemistry. Figure 5C: Soft agar assay showing significant reduction in colony number in EWS502 transfected with junction
deletion construct, compared to vector control and wild type EWS502. Figure 5D: Photographs of live pCDNA/FLAG and pCDNA/FLAG/Junction
(aa 251–280) stably expressing EWS502 cells in culture obtained at 10X magnification.
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EWS502 cell line. EWS-FLI1 knockdown based studies
and transcriptional profiling data [22] of various Ewing’s
sarcoma cell lines have shown that gene like NR0B1,
NKX2.2, EZH2, GLI1 are up regulated by EWS-FLI1.
Functional studies revealed that ongoing expression of
these genes are required for the transformed phenotype
of Ewing’s sarcoma and reduction of any of these genes
either in transcript level or in protein levels resulted in a
significant reduction of oncogenic transformation in
various Ewing’s sarcoma cells [23-26]. This is in agree-
ment with our results. In the present study we found
more than 2 folds down regulation of NR0B1, NKX2.2
and GLI1 in EWS502 cell line in the presence of junc-
tion construct (compared to vector control) which could
be the probable reason for the reduced tumorigenicity of
junction construct transfected EWS502 cell line in vitro.Previous studies have shown that TGFβRII is a major
down regulated target of EWS-FLI1 oncoprotein [27] and
introduction of normal TGFβRII into Ewing’s sarcoma cell
lines restores TGFβ sensitivity and blocks tumorigenicity.
We observed a significant up regulation in TGFβRII and
KLF2 in the junction construct transfected EWS502 cells,
which again supports the reduced tumorigenicity of junc-
tion construct transfected EWS502 cell line.
Earlier studies have shown that Ewing’s sarcoma-
specific EWS-ETS oncoproteins were capable of activat-
ing Cyclin D1 promoter in transient transfections of
tissue culture cells [28,29]. Strong oncogenes such as
c-MYC and Cyclin D1 appear to be up regulated by
EWS-FLI1 in some models [30,31]. In our study we
found 2.4 folds down regulation of Cyclin D1 and 1.48
fold down regulation of c-MYC in junction construct
transfected EWS502 compared to vector control.
Figure 6 Real Time PCR for EWS-FLI1 target genes and genes involved in EMT: A: Real time PCR for target genes showing down
regulation of EWS-FLI1 regulated genes like Cyclin D1, c-MYC, GLI1, NKX2.2, EZH2, NROB1 in junction construct (aa 251–280)
transfected EWS502 cell line relative to vector control pcDNA-EWS502. Figure 6B: Real Time PCR for EMT markers showing down regulation
Fibronectin, Slug, Vimentin, N-Cadherin and up regulation of E-Cadherin in junction region transfected EWS502 cell line relative to vector control
pCDNA-EWS502. Figure 6C: Immunoblot analysis of E-Cadherin, Vimentin and Beta Actin expression in MCF-7, pCDNA/FLAG and pCDNA/FLAG/
Junction (aa 251–280) stably expressing EWS502 cells. Figure 6D: Quantitation of Immunoblot intensities. The individual intensities are presented
as percent total intensity . The total intensity was obtained by adding all the intensities from the individual bands.
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in earlier studies have shown that Ewing’s sarcoma cells
are positive for Vimentin [32]. Ewing's sarcoma cell lines
produce a complex extra cellular matrix containing
Fibronectin [33]. Previous studies have shown that Slug
expression triggers EMT and its expression is inversely
correlated with E-Cadherin expression [34]. In the
present work we have suggested that down regulation of
mesenchymal markers and up regulation of epithelial
marker like E-Cadherin in EWS502 cell line, in the pres-
ence of junction construct may be a probable reason for
the suppression of tumorigenicity in vitro.
Conclusions
We for the first time have identified a region encompass-
ing the junction region of EWS-FLI1 protein to be part of
putative small molecule binding sites (aa 251 – 343) and
this region can be expressed in the soluble form which
could pave the way for structural characterization of thisregion. Our study also indicates a propensity for a short
junction construct (aa 251 – 280 a 30 amino acid-peptide)
to exhibit a dominant negative effect on the functions of
wild type EWS-FLI1 protein by inhibiting target gene ex-
pression and tumorigenicity in vitro.
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